Innovative Ketamine Formulations: Enhancing Therapeutic Efficacy and Safety.
ACS medicinal chemistry letters August 8, 2024 DOI: 10.1021/acsmedchemlett.4c00330 via PubMed
Summary
AI-generated from the abstractKetamine, originally an anesthetic, is now used for depression and chronic pain but causes side effects like hallucinations and dizziness from rapid blood concentration spikes. Recent patents describe new delivery methods: subcutaneous injections, ketamine conjugates with other molecules, and dual-release formulations combined with aspirin. These innovations aim to improve how the drug is absorbed and processed in the body, potentially enhancing therapeutic outcomes and safety.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Ketamine-therapy Drug-delivery-systems Pharmaceutical-innovation Depression-treatment |
| Citations | 1 |
| Key finding | Recent patents for subcutaneous injectable compositions, ketamine conjugates, and dual-release formulations with aspirin may improve ketamine's pharmacokinetic profiles, therapeutic outcomes, and safety. |
Abstract
Ketamine, originally developed as an anesthetic, has shown significant potential for treating depression, chronic pain, and other conditions. However, its conventional formulations often result in side effects such as hallucinations and dizziness due to rapid spikes in blood concentration. This article explores recent patents that optimize ketamine delivery and efficacy: subcutaneous injectable compositions, ketamine conjugates with various molecules, and dual-release formulations combining ketamine with aspirin. These innovations promise to improve ketamine-based treatments' pharmacokinetic profiles, therapeutic outcomes, and safety.